Abstract: A vehicle system includes a plurality of devices and a controller. The plurality of devices are mounted on the vehicle, and each of the devices implements a function having a safety standard of a predetermined level set therein. The controller is capable of executing processing related to the safety standard on the devices, and includes a plurality of ECUs respectively allocated for the levels of the safety standards. The plurality of ECUs are respectively connected to the devices in which the safety standards of the allocated levels are set without being connected to the devices in which the safety standards of different levels are set, and execute, on the connected devices, processing related to the safety standards according to the allocated levels. Accordingly, the vehicle system can appropriately construct a system that secures safety.

Abstract: A therapeutic agent or prophylactic agent for a disease requiring an anti-foaming action for a cell and/or an inhibitory action for acyl-CoA cholesterol acyltransferase in treatment or prevention, characterized in that the therapeutic agent or prophylactic agent comprises as an effective ingredient a processed product derived from Peucedanum japonicum.

Abstract: The present invention provides a novel chalcone compound, its derivative or a salt thereof, each having a suppressive action of NO production or an inhibitory action of aldose reductase. In addition, the present invention provides a medicament, a food, a beverage or a feed having a therapeutic or prophylactic effect for a disease showing sensitivity to the compound, by utilizing the physiological actions of the compound.

Abstract: According to the present invention, there are provided kneading-free Angelica keiskei tea leaves obtainable by a treatment comprising a step for roast-heating a dried material of Angelica keiskei; an Angelica keiskei tea beverage produced by using the kneading-free Angelica keiskei tea leaves; and a process for producing thereof. The Angelica keiskei tea leaves are preferably heated at a heating temperature of 100° C. to 150° C. in the roast-heating treatment, and the dried material of Angelica keiskei to be subjected to the roast-heating is preferably obtained by drying in a dried system after blanching and has a moisture content of 20% or less. Further, according to the present invention, there is also provided an Angelica keiskei chalcone function-formulated beverage comprising formulated Angelica keiskei chalcones that are components specific to Angelica keiskei.

Abstract: The present invention relates to a chalcone compound represented by the following general formula: wherein R1 and R2 are taken together with the carbon atom to which they are bound, respectively, to form a hydroxydimethyl hexane ring, or where R1 is a hydroxyl group, R2 is an isohexenyl group, a derivative thereof, or a salt thereof. Also, the present invention relates to a therapeutic agent or prophylactic agent for a disease requiring neuronal protection, suppression for nitrogen monoxide (NO) production, inhibition for aldose reductase or suppression for interleukin production, and a food, beverage or feed for treatment or prevention of the above-mentioned disease, characterized in that each comprises the above-mentioned compound as an effective ingredient.

Abstract: The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed for treating or preventing a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for enhancement of glucose uptake into a cell, and an agent for induction of an adipocyte differentiation, each comprising as an effective ingredient a processed product derived from a plant belonging to Umbelliferae.

Abstract: The present invention relates to a therapeutic agent or prophylactic agent for a disease requiring promotion of osteogenesis or enhancement of bone morphogenetic protein production, an agent for promotion of osteogenesis or an agent for enhancement of bone morphogenetic protein production, and a food, beverage or feed for promotion of osteogenesis or enhancement of bone morphogenetic protein production, characterized in that each comprises as an effective ingredient a processed product derived from a plant. Also, the present invention relates to a method for measuring an enhancing action for bone morphogenetic protein production, a method for screening a substance having an enhancing action for bone morphogenetic protein production, and a method for preparing a substance having an enhancing action for bone morphogenetic protein production, each method using a specified cell.

Abstract: The present invention provides a novel chalcone compound, its derivative or a salt thereof, each having a suppressive action of NO production or an inhibitory action of aldose reductase. In addition, the present invention provides a medicament, a food, a beverage or a feed having a therapeutic or prophylactic effect for a disease showing sensitivity to the compound, by utilizing the physiological actions of the compound.

Abstract: The present invention provides an extract obtainable by extracting a plant belonging to Umbelliferae, or a processed product thereof, with a water-containing alcohol; a process for preparing the extract; a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response and/or diabetic complications, characterized in that the therapeutic agent or prophylactic agent comprises as an effective ingredient the extract as defined above; an agent for an insulin-mimetic action, characterized in that the agent comprises as an effective ingredient the extract as defined above; a food, beverage or feed, comprising the extract as defined above; an agent for enhancing glucose uptake into a cell, characterized in that the agent comprises as an effective ingredient the extract as defined above; to an agent for inducing differentiation into an adipocyte, characterized in that the agent comprises as an effective ingredient the extract as defined above; and an inhibi

Abstract: A printer includes an ink jet head, a recovery unit, a moving unit, a conveying unit and a cover. The ink jet head performs printing on a printing medium and has an ink ejection port on an ejection port forming surface. The recovery unit is used for a recovery process for maintaining an ink ejection state of the ink jet head in a good condition. The recovery unit includes a cap for covering the ejection port forming surface, a wiping member for wiping the ejection port forming surface, and an absorbing member for receiving ink ejected from the ejection port of the ink jet head. The moving unit moves the recovery unit to a position where the recovery unit faces the ink jet head and to a position where the recovery unit does not face the ink jet head, the ejection forming surface of which is oriented toward the printing medium. The conveying unit conveys the printing medium to be printed by the ink jet head. The cover contains the ink jet head and the recovery unit.

Abstract: The present invention relates to a therapeutic agent or prophylactic agent for a disease requiring enhancement of bone morphogenetic protein production or promotion of osteogenesis; an agent for enhancement of bone morphogenetic protein production or an agent for promotion of osteogenesis, a food, beverage or feed for enhancement of bone mornhogenetic protein production or promotion of osteogenesis, characterized in that each comprises as an effective ingredient at least one compound selected from the group consisting of (a) an acidic saccharide, (b) a polyacrylic acid, (c) chlorogenic acid and (d) an oxidation processed product of chlorogenic acid, or an extract derived from algae.

Abstract: The present invention relates to a therapeutic agent or prophylactic agent for a disease requiring promotion of osteogenesis or enhancement of bone morphogenetic protein production, an agent for promotion of osteogenesis or an agent for enhancement of bone morphogenetic protein production, and a food, beverage or feed for promotion of osteogenesis or enhancement of bone morphogenetic protein production, characterized in that each comprises as an effective ingredient a processed product derived from a plant. Also, the present invention relates to a method for measuring an enhancing action for bone morphogenetic protein production, a method for screening a substance having an enhancing action for bone morphogenetic protein production, and a method for preparing a substance having an enhancing action for bone morphogenetic protein production, each method using a specified cell.

Abstract: The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed for treating or preventing a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for enhancement of glucose uptake into a cell, and an agent for induction of an adipocyte differentiation, each comprising as an effective ingredient a processed product derived from a plant belonging to Umbelliferae.

Abstract: A wheel bearing includes a sealing device 5 positioned between inner and outer members 1 and 2. This sealing device 5 includes an elastic member 14, which eventually forms an encoder grid and is provided on a first annular sealing plate 11. A second annular sealing plate 12 is provided with sealing lips 16a to 16c. An engagement 18 between a cylindrical wall 11a of the first annular sealing plate 11 and the inner member 1 is provided with an elastic member 20 made of a material dissimilar to that for the elastic material 14. This elastic member 20 may be a rubber coated layer, resin paint layer, a thin film of adhesive material or a ring-shaped rubber member. Thereby, any possible ingress of water across an engagement surface of the annular sealing plate is prevented, accompanied by increase of the lifetime of the bearing, with no problem associated with separation and displacement of the annular sealing plates. The magnetic flux density can also be easily secured.

Abstract: The present invention relates to a novel chalcone compound represented by the following general formula: wherein R1 and R2 are taken together with the carbon atom to which they are bound, respectively, to form a hydroxydimethyl hexane ring, or where R1 is a hydroxyl group, R2 is an isohexenyl group, a derivative thereof, or a salt thereof. Also, the present invention relates to a therapeutic agent or prophylactic agent for a disease requiring neuronal protection, suppression for nitrogen monoxide (NO) production, inhibition for aldose reductase or suppression for interleukin production, and a food, beverage or feed for treatment or prevention of the above-mentioned disease, characterized in that each comprises the above-mentioned compound as an effective ingredient.

Abstract: The present invention relates to a therapeutic agent or prophylactic agent for a disease requiring enhancement of nerve growth factor (NGF) production upon treatment or prevention, an enhancing agent for nerve growth factor production, and a food, beverage or feed for enhancing nerve growth factor production, characterized in that each comprises as an effective ingredient a compound selected from the group consisting of soyasaponin compounds, soyasapogenin compounds, glycyrrhizin and salts thereof. In addition, the present invention relates to a novel soyasaponin compound and a novel soyasapogenin compound, having an action for enhancement of NGF production.

Abstract: A printer includes an ink jet head, a recovery unit, a moving unit, a conveying unit and a cover. The ink jet head performs printing on a printing medium and has an ink ejection port on an ejection port forming surface. The recovery unit is used for a recovery process for maintaining an ink ejection state of the ink jet head in a good condition. The recovery unit includes a cap for covering the ejection port forming surface, a wiping member for wiping the ejection port forming surface, and an absorbing member for receiving ink ejected from the ejection port of the ink jet head. The moving unit moves the recovery unit to a position where the recovery unit faces the ink jet head and to a position where the recovery unit does not face the ink jet head, the ejection forming surface of which is oriented toward the printing medium. The conveying unit conveys the printing medium to be printed by the ink jet head. The cover contains the ink jet head and the recovery unit.

Abstract: In a recovering apparatus for recovering ink ejecting ports forming a plane of an ink jet head, an ink absorbing member is disposed inward of a cap and proximate to the ink ejecting ports, facing the ink ejecting ports at a predetermined distance therefrom. Large ink droplets or water droplets adhering to the ink ejecting ports are then absorbed in the absorbing member. Thereafter, the plane of the ink jet heads with the ink ejecting ports is cleanly wiped by a wiping member, thereby preventing scattering of ink droplets or water droplets away from the ink ejecting ports. A trough is located adjacent to each head, and the recovering apparatus is disposed with respect to the trough so that a distance between the recovering apparatus and the ink jet head can be reduced, thereby permitting a compact arrangement of the recovering apparatus and the ink jet head.

Abstract: According to the present invention, there is provided a medicament for oral administration or intravenous administration that is effective for a disease requiring enhancement of nerve growth factor production, comprising as an effective ingredient a pulverized product and/or extract obtained from Humulus lupulus and/or Angelica keiskei koidz., or xanthohumol and/or a pharmacologically acceptable salt thereof. The medicament is useful as a therapeutic agent or prophylactic agent for a disease requiring enhancement of nerve growth factor production, such as dementia or a nerve disorder.

Abstract: According to the present invention, there is provided a therapeutic agent or prophylactic agent that is effective for a disease requiring enhancement of nerve growth factor production for treatment or prevention, comprising as an effective ingredient an aqueous extract of mushrooms. These agents are usable in the treatment or prevention of a disease requiring enhancement of nerve growth factor production such as dementia or nerve disorder.